Basildon, UK, May 11 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce that the Food and Drug Administration (“FDA”) has granted supplement approval to the manufacturing site transfer of Naproxen Suspension in the US.
This has triggered the second and final US$ 2 million payment in a total transaction of US$4.25 million.
For further information: pharmanovia.com
Pharmanovia Press Contact
Kate Antonopoulos, Corporate Marketing & Communications Manager
Phone: +44 1268 943857